Cabazitaxel: 7 agencies, 2011–2022
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused cabazitaxel: all 13 decisive outcomes across 6 agencies were positive or positive with restrictions.
Assessment has run over 10.8 years, from 13 Oct 2011 at AWMSG (Wales) to 2022 at PBAC (Australia).
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for cabazitaxel by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess cabazitaxel, on 13 Oct 2011; PBAC (Australia) did not open a file until 2021 — an unusually long tail of 9.8 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 7 years in total.
2 of the 7 agencies here assessed cabazitaxel more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for cabazitaxel.
The full ledger for cabazitaxel reads 10 recommended, 3 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2022 | Prostate cancer | Recommended | source |
| HAS (France) | 29 Jun 2022 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AOTMIT (Poland) | 13 May 2019 | programu lekowego „Kabazytaksel w leczeniu opornego na kastrację raka gruczołu krokowego (ICD-10 C61) | recommended conditionally | source |
| SMC (Scotland) | 12 Dec 2016 | Cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously … | accepted (restricted) | source |
| NICE (England) | 25 May 2016 | NICE TA391 | recommended (optimised) | source |
9 further decisions for cabazitaxel, across 4 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- docetaxel — same ATC class L01C — Antineoplastics
- paclitaxel — same ATC class L01C — Antineoplastics
- irinotecan — same ATC class L01C — Antineoplastics
- topotecan — same ATC class L01C — Antineoplastics
- trabectedin — same ATC class L01C — Antineoplastics
- vinorelbine — same ATC class L01C — Antineoplastics
Coverage: 14 decisions for cabazitaxel from 7 agencies, 2011 to 2022. Data to 7 Sep 2026. ATC class L01C — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.